Positron (OTCMKTS:POSC) versus DarioHealth (NASDAQ:DRIO) Financial Review

DarioHealth (NASDAQ:DRIO) and Positron (OTCMKTS:POSC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.

Risk & Volatility

DarioHealth has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Positron has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500.

Profitability

This table compares DarioHealth and Positron’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DarioHealth	-192.23%	-60.52%	-37.08%
Positron	-1,996.75%	-996.81%	-272.52%

Insider & Institutional Ownership

33.4% of DarioHealth shares are held by institutional investors. 3.5% of DarioHealth shares are held by insiders. Comparatively, 17.2% of Positron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares DarioHealth and Positron”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$22.36 million	2.56	-$41.71 million	($8.88)	-0.88
Positron	$460,000.00	119.97	-$10.60 million	($0.33)	-5.09

Positron has lower revenue, but higher earnings than DarioHealth. Positron is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for DarioHealth and Positron, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1	1	1	0	2.00
Positron	0	0	0	0	0.00

DarioHealth presently has a consensus target price of $10.50, indicating a potential upside of 34.79%. Given DarioHealth’s stronger consensus rating and higher probable upside, equities analysts plainly believe DarioHealth is more favorable than Positron.

Summary

DarioHealth beats Positron on 10 of the 14 factors compared between the two stocks.

About DarioHealth

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

About Positron

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.